Medivation, Inc.

  • This Biotech’s Single Egg Will Never Hatch

    By Leo Sun - August 16, 2013 | Tickers: DNDN, JNJ, MDVN

    Shares of Dendreon (NASDAQ: DNDN) have taken a beating over the past month, falling more than 30% over the past week after sales of its prostate cancer therapy Provenge fell short of analyst estimates. Dendreon’s decline illustrates a classic dilemma in biotech investing -- what happens when a company only has a single egg in its basket, and that egg fails to hatch?

    The single egg cracks

    Dendreon only has more »

  • Biotechs With Prostate Cancer Treatments

    By Terry Chrisomalis - July 31, 2013 | Tickers: DNDN, JNJ, MDVN

    There are many types of biotech companies out there with tremendous value. Today, I will focus on the ones that target prostate cancer. Investors should look at these types of companies as they are starting to make good progress on their research. Another reason is that there is a huge billion dollar opportunity in this sector.

    When I say a billion dollar opportunity, I mean it literally. The sector is more »

  • Is Time Running Out for This Fallen Biotech?

    By Sherrie Stone - July 17, 2013 | Tickers: DNDN, JNJ, MDVN

    There’s a lot to notice from Johnson & Johnson’s (NYSE: JNJ) earnings -- the company announced a very solid quarter. But the one thing that really stood out is the high sales that the company produced from its prostate cancer drug Zytiga. Does Zytiga's succes further indicate that time is running out for Dendreon’s (NASDAQ: DNDN) Provenge?

    Zytiga’s not slowing down

    Johnson & Johnson’s total sales for more »

  • Hedge Fund Adage Capital Management’s Small Cap Picks

    By Meena Krishnamsetty - April 19, 2013 | Tickers: AWI, PLCE, FTR, MDVN, WBC

    The most popular small cap stocks among hedge funds outperform the S&P 500 by an average of 18 percentage points per year, according to our research on 13F filings. We think that this is because small cap stocks, which we define as those between $1 billion and $5 billion in market capitalization, receive less attention from large institutional investors such as mutual funds and so are more likely to more »

  • Is Medivation Still A Buy?

    By Terry Chrisomalis - April 18, 2013 | Tickers: DNDN, JNJ, MDVN

    It seems that Medivation (NASDAQ: MDVN) had a great year in 2012, and so far the momentum seems it will keep going through all of 2013 as well. Medivation is a biotechnology stock that targets diseases with limited treatment options. The company had a rough past when it had partnered with Pfizer, with a drug known as Dimebon. 

    Dimebon had made it up to Phase III, where it had failed more »

  • Hedge Fund Adage Capital Management’s Small Cap Picks

    By Meena Krishnamsetty - April 16, 2013 | Tickers: AWI, PLCE, FTR, MDVN, WBC

    The most popular small cap stocks among hedge funds outperform the S&P 500 by an average of 18 percentage points per year, according to our research on 13F filings (learn more about hedge funds' small cap picks). We think that this is because small cap stocks, which we define as those between $1 billion and $5 billion in market capitalization, receive less attention from large institutional investors such as more »

  • Adage Capital Management Owns 5.4% of This Biotech Stock

    By Meena Krishnamsetty - April 10, 2013 | Tickers: ABT, AMRN, BIIB, DNDN, MDVN

    According to a 13G filed with the SEC, Adage Capital Management, a large hedge fund managed by Phil Gross and Robert Atchinson, owns just over 4 million shares of Medivation (NASDAQ: MDVN), a $3.6 billion market cap biotechnology company. Our database of 13F filings shows Adage with a position of 2.1 million shares as of the beginning of January, so in the last three months the fund has more »

  • Is Medivation Still A Buy?

    By Terry Chrisomalis - April 9, 2013 | Tickers: DNDN, JNJ, MDVN

    It seems that Medivation (NASDAQ: MDVN) had a great year in 2012, and so far the momentum seems it will keep going through all of 2013 as well. Medivation is a biotechnology stock that targets diseases with limited treatment options. The company had a rough past though, when it had partnered with Pfizer with a drug known as Dimebon. 

    Dimebon had made it up to phase three, where it had more »

  • Adage Capital Management Owns 5.4% of This Biotech Stock

    By Meena Krishnamsetty - April 8, 2013 | Tickers: ABT, AMRN, BIIB, DNDN, MDVN

    According to a 13G filed with the SEC, Adage Capital Management, a large hedge fund managed by Phil Gross and Robert Atchinson, owns just over 4 million shares of Medivation (NASDAQ: MDVN), a $3.6 billion market cap biotechnology company. Our database of 13F filings shows Adage with a position of 2.1 million shares as of the beginning of January, so in the last three months the fund has more »

  • A Magical Drug that Could Change Lives

    By Piyush Arora - March 25, 2013 | Tickers: DNDN, JNJ, MDVN

    The biotech sector is perhaps the most volatile and risk-prone sector in the market, but investors still love it. Medical science is leaping forward and new drugs keep hitting the Street, but the hunt for the “safer and more effective drug” is always on. It’s for this reason that we often see contrarians being rewarded massively for their daring positions. The company in focus is Dendreon Corporation (NASDAQ: DNDNmore »)

  • Revitalize Your Portfolio With This Drugmaker

    By Rahul Giria - March 11, 2013 | Tickers: DNDN, MDVN, NVS

    Dendreon (NASDAQ: DNDN) has been struggling since summer 2011, when the company decreased its sales estimates for its flagship cancer drug Provenge. As a result, shares have taken a huge hit since then. Provenge faces stiff competition from Medivation’s (NASDAQ: MDVN) Xtandi and Johnson & Johnson’s (NYSE: JNJ) Zytiga. Yet I believe now's the right time to invest in Dendreon's stock. Let assess why.

    Financials

    Dendreon surprised more »

  • Will Cost Cutting Offset Competitive Pressures For This Biotech In 2013?

    By Jordo Bivona - February 6, 2013 | Tickers: ABBV, DNDN, JNJ, MDVN

    Dendreon (NASDAQ: DNDN) is recovering from lackluster sales of its sole drug on the market, Provenge. The prostate cancer treatment has been hit hard by reimbursement concerns that have led the company to make some big cuts, including the closing of a production plant and layoffs, to make up for lost sales. Have these changes been enough? With a number of other prostate cancer drugs on the market, it is more »

  • Five Healthcare Stocks With Mass Movement

    By Brian Nichols - January 22, 2013 | Tickers: ARNA, CLSN, MDVN, SPPI

    Healthcare stocks are always the most volatile in the market, regardless of the market’s overall direction. On Tuesday we saw mass movement in this space from five high-profile stocks. Therefore, I am looking at this movement, determining what it means, and suggesting how to play it.

    Company

    Ticker

    Performance*

    Celsion Corporation

    (NASDAQ: CLSN)

    10.52%

    ACADIA Corporation

    (NASDAQ: CLSN)

    9.48%

    Medivation

    (NASDAQ: MDVN)

    4.20%

    Arena Pharmaceuticals

    (NASDAQ: ARNAmore »)

  • Is the Optimism Surrounding Provenge Reason to Buy?

    By Jordo Bivona - January 14, 2013 | Tickers: DNDN, JNJ, MDVN, NVS, TEVA

    Dendreon (NASDAQ: DNDN) recently sold its immunotherapy manufacturing facility based in Morris Plains, New Jersey to Novartis (NYSE: NVS) for $43 million in cash.

    The manufacturing facility has the capability to manufacture Provenge, the first cellular immunotherapy approved in the U.S. for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. The sale is part of a 12 month restructuring plan in which the company decided more »

  • Dendreon's Roller Coaster Still Rocking

    By Paul Springer - December 11, 2012 | Tickers: DNDN, JNJ, MDVN

    Volatility goes hand in hand with Biotech stocks, but prostate cancer treatment maker Dendreon Corp. (NASDAQ: DNDN) has had more than its fair share of gut-twisting centripetal price movement. Now that the stock is lying like a pig at four bucks and change, it bears looking at again, especially now that a new study is testing the company's principal medication in conjunction with other treatments.

    In addition to the more »

  • Can Anything Save Dendreon?

    By Jordo Bivona - September 7, 2012 | Tickers: DNDN, JNJ, MDVN

    As a longtime follower if not fan, I’m going to put in my two cents worth on Dendreon (NASDAQ: DNDN). Dendreon concerns me as investment in three key areas. Management, past and present, has made some terrible decisions. Dendreon invested in production capacity far exceeding the requirements of demand, forcing its New Jersey production facility to close and resulting in the dismissal of 600 workers. Long-term, this will save more »

  • Former Drug Developer Discovers Next-Generation Biotech Stocks

    By Streetwise Reports - June 22, 2012 | Tickers: ACHN, ACOR, AMRN, IDIX, MDVN

    Former Drug Developer Discovers Next-Generation Biotech Stocks

    By George S. Mack, The Life Sciences Report

    Management is the key ingredient

    Raghuram "Ram" Selvaraju, an analyst I recently interviewed for The Life Sciences Report, began his initial career in translational drug discovery at Serono in 2000 with early and remarkable success. As a young researcher he demonstrated real insight and ability when he discovered the first novel protein candidate ever developed more »

  • Dendreon: A Solid Long-Term Stock at $7

    By Jordo Bivona - May 21, 2012 | Tickers: DNDN, JNJ, MDVN

    Dendreon (NASDAQ: DNDN) is a groundbreaking biotechnology company engaged in the discovery and commercialization of cell-targeted cancer treatments. The stock, currently trading around $7, is down roughly 85% from its 52-week high of around $43, where it swapped hands last summer. However, in sharp contrast to the performance of the stock, its only marketed drug, Provenge, has steadily grown sales and proven to be a reliable source of cash flow more »

  • Dendreon Likely to Jump Higher on Strong Pipeline

    By Jordo Bivona - May 16, 2012 | Tickers: DNDN, JNJ, MDVN, PGNX, SNY

    Dendreon (NASDAQ: DNDN) has fallen 73% since last year. This is due mainly to the fact that Dendreon only has one FDA approved drug on the market, Provenge, a prostate cancer vaccine treatment. The company was expecting $400 million in sales in 2011, but reported less than $350 million. Despite this, I predict that Provenge sales will increase slowly, and the pipeline drugs, though years away from the market, will more »

  • Keryx: A Great Pick For Aggressive Investors

    By Bobby Fisher - March 26, 2012 | Tickers: CRIS, KERX, MDVN, MYGN

    There’s something to be said for investing in companies that have admirable objectives. Keryx Pharmaceuticals (NASDAQ: KERX) is trying to help cure bowel cancer. It’s a worthy goal given that the recovery prospects for patients at this moment are bleak. But does that make Keryx stock a great investment?

    The company’s stock has soared in the last few weeks with news of impending data from their phase more »

  • Page 1 of 2